| Fontana RJ, Kronfol Z, Lindsay KL, et al.
Changes in Mood States and Biomarkers During Peginterferon and Ribavirin Treatment of Chronic Hepatitis C. [JOURNAL ARTICLE]
Am J Gastroenterol 2008 Aug 21.
Abstract | Full Citation | Find Related Articles | | Fried MW, Jensen DM, Rodriguez-Torres M, et al.
Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: Randomized study of higher doses of peginterferon alpha-2a and ribavirin. [JOURNAL ARTICLE]
Hepatology 2008 Jun 9.
Abstract | Full Citation | | Bonkovsky HL, Tice AD, Yapp RG, et al.
Efficacy and Safety of Peginterferon Alfa-2a/Ribavirin in Methadone Maintenance Patients: Randomized Comparison of Direct Observed Therapy and Self-Administration. [JOURNAL ARTICLE]
Am J Gastroenterol 2008 Aug 5.
Abstract | Full Citation | Find Related Articles | | Nicot F, Legrand-Abravanel F, Lafont T, et al.
Serum concentrations of ribavirin and pegylated interferon and viral responses in patients infected with HIV and HCV. [JOURNAL ARTICLE]
J Med Virol 2008 Jul 22; 80(9):1523-1529.
Abstract | Full Citation | Find Related Articles | | Rodríguez-Torres M, Ríos-Bedoya CF, Ortiz-Lasanta G, et al.
Weight affect relapse rates in latinos with genotype 2/3 chronic hepatitis C (CHC) treated with peg IFN alfa-2a (Pegasys) 180 mcg/week and 800 mg daily of ribavirin for 24 weeks. [JOURNAL ARTICLE]
J Med Virol 2008 Jul 22; 80(9):1576-1580.
Abstract | Full Citation | Find Related Articles | | Hamer C
The impact of combination therapy with peginterferon alfa-2a and ribavirin on the energy intake and body weight of adult hepatitis C patients. [JOURNAL ARTICLE]
J Hum Nutr Diet 2008 Jul 18.
Abstract | Full Citation | | Moreau I, Levis J, Crosbie O, et al.
Correlation between pre-treatment quasispecies complexity and treatment outcome in chronic HCV genotype 3a. [JOURNAL ARTICLE]
Virol J 2008 Jul 9; 5(1):78.
Abstract | Full Citation | | Gelderblom HC, Zeuzem S, Weegink CJ, et al.
Inflammatory markers neopterin and alanine aminotransferase in HCV patients treated with HCV NS3*4A protease inhibitor telaprevir (VX-950) and/or peginterferon alfa-2a. [JOURNAL ARTICLE]
Scand J Gastroenterol 2008 Apr 10.:1-6.
Abstract | Full Citation | Find Related Articles | | Pagliano P, Costantini S, Gradoni L, et al.
Distinguishing visceral leishmaniasis from intolerance to pegylated interferon-alpha in a thalassemic splenectomized patient treated for chronic hepatitis C. [Case Reports, Journal Article]
Am J Trop Med Hyg 2008 Jul; 79(1):9-11.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Capanni M, Lorefice E, Benini MC, et al.
Occurrence of diffuse, poorly differentiated hepatocellular carcinoma during pegylated interferon plus ribavirin combination therapy for chronic hepatitis C. [Journal Article]
J Chemother 2008 Jun; 20(3):380-4.
Abstract | Full Citation | Find Related Articles |   |
|
| | Enter
www.unboundmedicine.com/medline
in your iPhone browser
or View our
Unbound MEDLINE
iPhone demo
Advertise on this site.
|
